'Guidelines' or marketing for non-steroidal anti-inflammatory drug and proton pump inhibitor use? (multiple letters)

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 12, 2004, Pages 1323-1324

  Graham, David Y ^a   Laine, L ^b   Dubois, R W ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Zynx Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; STOMACH SECRETION INHIBITOR; SUCRALFATE;

BACTERIAL INFECTION; BLEEDING; CLINICAL TRIAL; DRUG INDUSTRY; DUODENUM ULCER; HELICOBACTER PYLORI; HUMAN; LETTER; PERFORATION; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; STOMACH ULCER; ULCER; UPPER GASTROINTESTINAL BLEEDING;

EID: 3042796037     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01950.x     Document Type: Letter

References (0)